Treatment with the JAK1/2 inhibitor ruxolitinib reduces cytokine levels and inflammatory symptoms in most MPN patients highlighting a relevance of the inflammatory milieu for disease burden [83]. This evidence concerns the gene JAK1 and myeloproliferative disorder.